Open3.520 | Close3.350 |
Vol / Avg.768.088K / 210.509K | Mkt Cap73.040M |
Day Range3.090 - 3.558 | 52 Wk Range1.960 - 6.600 |
Ocuphire Pharma Stock (NASDAQ: OCUP) stock price, news, charts, stock research, profile.
Open3.520 | Close3.350 |
Vol / Avg.768.088K / 210.509K | Mkt Cap73.040M |
Day Range3.090 - 3.558 | 52 Wk Range1.960 - 6.600 |
Q3 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED) | ||||||
REV |
Q2 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -0.230 | -0.240 | -0.0100 | ||||
REV | 2.420M | 3.674M | 1.254M |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|---|---|---|---|---|---|---|
2023-08-14 | Cantor Fitzgerald | Kristen Kluska | Reiterates | OverweightOverweight | Maintains | - | 17.00 |
2023-08-14 | HC Wainwright & Co. | Matthew Caufield | Reiterates | BuyBuy | Maintains | - | 20.00 |
2023-05-16 | HC Wainwright & Co. | Matthew Caufield | Reiterates | BuyBuy | Maintains | - | 20.00 |
2023-03-31 | HC Wainwright & Co. | Matthew Caufield | Reiterates | Buy | Maintains | - | 20.00 |
Ticker | Company | Chg % | Mkt Cap |
---|---|---|---|
OCUP | Ocuphire Pharma | -1.15% | 73M |
SCYX | SCYNEXIS | 2.17% | 87.4M |
RANI | Rani Therapeutics Hldgs | -17.74% | 55.7M |
AQST | Aquestive Therapeutics | -0.67% | 99.4M |
ESPR | Esperion Therapeutics | 3.34% | 105.9M |
You can purchase shares of Ocuphire Pharma (NASDAQ: OCUP) through any online brokerage.
Other companies in Ocuphire Pharma’s space includes: SCYNEXIS (NASDAQ:SCYX), Rani Therapeutics Hldgs (NASDAQ:RANI), Aquestive Therapeutics (NASDAQ:AQST), Esperion Therapeutics (NASDAQ:ESPR) and Incannex Healthcare (NASDAQ:IXHL).
The latest price target for Ocuphire Pharma (NASDAQ: OCUP) was reported by Cantor Fitzgerald on Monday, August 14, 2023. The analyst firm set a price target for 17.00 expecting OCUP to rise to within 12 months (a possible 394.19% upside). 6 analyst firms have reported ratings in the last year.
The stock price for Ocuphire Pharma (NASDAQ: OCUP) is $3.44 last updated September 29, 2023 at 9:55 PM UTC.
There is no dividend information for Ocuphire Pharma.
Ocuphire Pharma’s Q3 earnings are confirmed for Friday, November 3, 2023.
There is no upcoming split for Ocuphire Pharma.
Ocuphire Pharma is in the Health Care sector and Pharmaceuticals industry. They are listed on the NASDAQ.
Ocuphire Pharma Stock (NASDAQ: OCUP) stock price, news, charts, stock research, profile.
Open3.520 | Close3.350 |
Vol / Avg.768.088K / 210.509K | Mkt Cap73.040M |
Day Range3.090 - 3.558 | 52 Wk Range1.960 - 6.600 |
Q3 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED) | ||||||
REV |
Q2 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -0.230 | -0.240 | -0.0100 | ||||
REV | 2.420M | 3.674M | 1.254M |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|---|---|---|---|---|---|---|
2023-08-14 | Cantor Fitzgerald | Kristen Kluska | Reiterates | OverweightOverweight | Maintains | - | 17.00 |
2023-08-14 | HC Wainwright & Co. | Matthew Caufield | Reiterates | BuyBuy | Maintains | - | 20.00 |
2023-05-16 | HC Wainwright & Co. | Matthew Caufield | Reiterates | BuyBuy | Maintains | - | 20.00 |
2023-03-31 | HC Wainwright & Co. | Matthew Caufield | Reiterates | Buy | Maintains | - | 20.00 |
Ticker | Company | Chg % | Mkt Cap |
---|---|---|---|
OCUP | Ocuphire Pharma | -1.15% | 73M |
SCYX | SCYNEXIS | 2.17% | 87.4M |
RANI | Rani Therapeutics Hldgs | -17.74% | 55.7M |
AQST | Aquestive Therapeutics | -0.67% | 99.4M |
ESPR | Esperion Therapeutics | 3.34% | 105.9M |
You can purchase shares of Ocuphire Pharma (NASDAQ: OCUP) through any online brokerage.
Other companies in Ocuphire Pharma’s space includes: SCYNEXIS (NASDAQ:SCYX), Rani Therapeutics Hldgs (NASDAQ:RANI), Aquestive Therapeutics (NASDAQ:AQST), Esperion Therapeutics (NASDAQ:ESPR) and Incannex Healthcare (NASDAQ:IXHL).
The latest price target for Ocuphire Pharma (NASDAQ: OCUP) was reported by Cantor Fitzgerald on Monday, August 14, 2023. The analyst firm set a price target for 17.00 expecting OCUP to rise to within 12 months (a possible 394.19% upside). 6 analyst firms have reported ratings in the last year.
The stock price for Ocuphire Pharma (NASDAQ: OCUP) is $3.44 last updated September 29, 2023 at 9:55 PM UTC.
There is no dividend information for Ocuphire Pharma.
Ocuphire Pharma’s Q3 earnings are confirmed for Friday, November 3, 2023.
There is no upcoming split for Ocuphire Pharma.
Ocuphire Pharma is in the Health Care sector and Pharmaceuticals industry. They are listed on the NASDAQ.
Ocuphire Pharma Stock (NASDAQ: OCUP) stock price, news, charts, stock research, profile.
Open3.520 | Close3.350 |
Vol / Avg.768.088K / 210.509K | Mkt Cap73.040M |
Day Range3.090 - 3.558 | 52 Wk Range1.960 - 6.600 |
Q3 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED) | ||||||
REV |
Q2 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -0.230 | -0.240 | -0.0100 | ||||
REV | 2.420M | 3.674M | 1.254M |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|---|---|---|---|---|---|---|
2023-08-14 | Cantor Fitzgerald | Kristen Kluska | Reiterates | OverweightOverweight | Maintains | - | 17.00 |
2023-08-14 | HC Wainwright & Co. | Matthew Caufield | Reiterates | BuyBuy | Maintains | - | 20.00 |
2023-05-16 | HC Wainwright & Co. | Matthew Caufield | Reiterates | BuyBuy | Maintains | - | 20.00 |
2023-03-31 | HC Wainwright & Co. | Matthew Caufield | Reiterates | Buy | Maintains | - | 20.00 |
Ticker | Company | Chg % | Mkt Cap |
---|---|---|---|
OCUP | Ocuphire Pharma | -1.15% | 73M |
SCYX | SCYNEXIS | 2.17% | 87.4M |
RANI | Rani Therapeutics Hldgs | -17.74% | 55.7M |
AQST | Aquestive Therapeutics | -0.67% | 99.4M |
ESPR | Esperion Therapeutics | 3.34% | 105.9M |
You can purchase shares of Ocuphire Pharma (NASDAQ: OCUP) through any online brokerage.
Other companies in Ocuphire Pharma’s space includes: SCYNEXIS (NASDAQ:SCYX), Rani Therapeutics Hldgs (NASDAQ:RANI), Aquestive Therapeutics (NASDAQ:AQST), Esperion Therapeutics (NASDAQ:ESPR) and Incannex Healthcare (NASDAQ:IXHL).
The latest price target for Ocuphire Pharma (NASDAQ: OCUP) was reported by Cantor Fitzgerald on Monday, August 14, 2023. The analyst firm set a price target for 17.00 expecting OCUP to rise to within 12 months (a possible 394.19% upside). 6 analyst firms have reported ratings in the last year.
The stock price for Ocuphire Pharma (NASDAQ: OCUP) is $3.44 last updated September 29, 2023 at 9:55 PM UTC.
There is no dividend information for Ocuphire Pharma.
Ocuphire Pharma’s Q3 earnings are confirmed for Friday, November 3, 2023.
There is no upcoming split for Ocuphire Pharma.
Ocuphire Pharma is in the Health Care sector and Pharmaceuticals industry. They are listed on the NASDAQ.
Ocuphire Pharma Stock (NASDAQ: OCUP) stock price, news, charts, stock research, profile.
Open3.520 | Close3.350 |
Vol / Avg.768.088K / 210.509K | Mkt Cap73.040M |
Day Range3.090 - 3.558 | 52 Wk Range1.960 - 6.600 |
Q3 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED) | ||||||
REV |
Q2 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -0.230 | -0.240 | -0.0100 | ||||
REV | 2.420M | 3.674M | 1.254M |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|---|---|---|---|---|---|---|
2023-08-14 | Cantor Fitzgerald | Kristen Kluska | Reiterates | OverweightOverweight | Maintains | - | 17.00 |
2023-08-14 | HC Wainwright & Co. | Matthew Caufield | Reiterates | BuyBuy | Maintains | - | 20.00 |
2023-05-16 | HC Wainwright & Co. | Matthew Caufield | Reiterates | BuyBuy | Maintains | - | 20.00 |
2023-03-31 | HC Wainwright & Co. | Matthew Caufield | Reiterates | Buy | Maintains | - | 20.00 |
Ticker | Company | Chg % | Mkt Cap |
---|---|---|---|
OCUP | Ocuphire Pharma | -1.15% | 73M |
SCYX | SCYNEXIS | 2.17% | 87.4M |
RANI | Rani Therapeutics Hldgs | -17.74% | 55.7M |
AQST | Aquestive Therapeutics | -0.67% | 99.4M |
ESPR | Esperion Therapeutics | 3.34% | 105.9M |
You can purchase shares of Ocuphire Pharma (NASDAQ: OCUP) through any online brokerage.
Other companies in Ocuphire Pharma’s space includes: SCYNEXIS (NASDAQ:SCYX), Rani Therapeutics Hldgs (NASDAQ:RANI), Aquestive Therapeutics (NASDAQ:AQST), Esperion Therapeutics (NASDAQ:ESPR) and Incannex Healthcare (NASDAQ:IXHL).
The latest price target for Ocuphire Pharma (NASDAQ: OCUP) was reported by Cantor Fitzgerald on Monday, August 14, 2023. The analyst firm set a price target for 17.00 expecting OCUP to rise to within 12 months (a possible 394.19% upside). 6 analyst firms have reported ratings in the last year.
The stock price for Ocuphire Pharma (NASDAQ: OCUP) is $3.44 last updated September 29, 2023 at 9:55 PM UTC.
There is no dividend information for Ocuphire Pharma.
Ocuphire Pharma’s Q3 earnings are confirmed for Friday, November 3, 2023.
There is no upcoming split for Ocuphire Pharma.
Ocuphire Pharma is in the Health Care sector and Pharmaceuticals industry. They are listed on the NASDAQ.
Ocuphire Pharma Stock (NASDAQ: OCUP) stock price, news, charts, stock research, profile.
Open3.520 | Close3.350 |
Vol / Avg.768.088K / 210.509K | Mkt Cap73.040M |
Day Range3.090 - 3.558 | 52 Wk Range1.960 - 6.600 |
Q3 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED) | ||||||
REV |
Q2 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -0.230 | -0.240 | -0.0100 | ||||
REV | 2.420M | 3.674M | 1.254M |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|---|---|---|---|---|---|---|
2023-08-14 | Cantor Fitzgerald | Kristen Kluska | Reiterates | OverweightOverweight | Maintains | - | 17.00 |
2023-08-14 | HC Wainwright & Co. | Matthew Caufield | Reiterates | BuyBuy | Maintains | - | 20.00 |
2023-05-16 | HC Wainwright & Co. | Matthew Caufield | Reiterates | BuyBuy | Maintains | - | 20.00 |
2023-03-31 | HC Wainwright & Co. | Matthew Caufield | Reiterates | Buy | Maintains | - | 20.00 |
Ticker | Company | Chg % | Mkt Cap |
---|---|---|---|
OCUP | Ocuphire Pharma | -1.15% | 73M |
SCYX | SCYNEXIS | 2.17% | 87.4M |
RANI | Rani Therapeutics Hldgs | -17.74% | 55.7M |
AQST | Aquestive Therapeutics | -0.67% | 99.4M |
ESPR | Esperion Therapeutics | 3.34% | 105.9M |
You can purchase shares of Ocuphire Pharma (NASDAQ: OCUP) through any online brokerage.
Other companies in Ocuphire Pharma’s space includes: SCYNEXIS (NASDAQ:SCYX), Rani Therapeutics Hldgs (NASDAQ:RANI), Aquestive Therapeutics (NASDAQ:AQST), Esperion Therapeutics (NASDAQ:ESPR) and Incannex Healthcare (NASDAQ:IXHL).
The latest price target for Ocuphire Pharma (NASDAQ: OCUP) was reported by Cantor Fitzgerald on Monday, August 14, 2023. The analyst firm set a price target for 17.00 expecting OCUP to rise to within 12 months (a possible 394.19% upside). 6 analyst firms have reported ratings in the last year.
The stock price for Ocuphire Pharma (NASDAQ: OCUP) is $3.44 last updated September 29, 2023 at 9:55 PM UTC.
There is no dividend information for Ocuphire Pharma.
Ocuphire Pharma’s Q3 earnings are confirmed for Friday, November 3, 2023.
There is no upcoming split for Ocuphire Pharma.
Ocuphire Pharma is in the Health Care sector and Pharmaceuticals industry. They are listed on the NASDAQ.
Ocuphire Pharma Stock (NASDAQ: OCUP) stock price, news, charts, stock research, profile.
Open3.520 | Close3.350 |
Vol / Avg.768.088K / 210.509K | Mkt Cap73.040M |
Day Range3.090 - 3.558 | 52 Wk Range1.960 - 6.600 |
Q3 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED) | ||||||
REV |
Q2 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -0.230 | -0.240 | -0.0100 | ||||
REV | 2.420M | 3.674M | 1.254M |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|---|---|---|---|---|---|---|
2023-08-14 | Cantor Fitzgerald | Kristen Kluska | Reiterates | OverweightOverweight | Maintains | - | 17.00 |
2023-08-14 | HC Wainwright & Co. | Matthew Caufield | Reiterates | BuyBuy | Maintains | - | 20.00 |
2023-05-16 | HC Wainwright & Co. | Matthew Caufield | Reiterates | BuyBuy | Maintains | - | 20.00 |
2023-03-31 | HC Wainwright & Co. | Matthew Caufield | Reiterates | Buy | Maintains | - | 20.00 |
Ticker | Company | Chg % | Mkt Cap |
---|---|---|---|
OCUP | Ocuphire Pharma | -1.15% | 73M |
SCYX | SCYNEXIS | 2.17% | 87.4M |
RANI | Rani Therapeutics Hldgs | -17.74% | 55.7M |
AQST | Aquestive Therapeutics | -0.67% | 99.4M |
ESPR | Esperion Therapeutics | 3.34% | 105.9M |
You can purchase shares of Ocuphire Pharma (NASDAQ: OCUP) through any online brokerage.
Other companies in Ocuphire Pharma’s space includes: SCYNEXIS (NASDAQ:SCYX), Rani Therapeutics Hldgs (NASDAQ:RANI), Aquestive Therapeutics (NASDAQ:AQST), Esperion Therapeutics (NASDAQ:ESPR) and Incannex Healthcare (NASDAQ:IXHL).
The latest price target for Ocuphire Pharma (NASDAQ: OCUP) was reported by Cantor Fitzgerald on Monday, August 14, 2023. The analyst firm set a price target for 17.00 expecting OCUP to rise to within 12 months (a possible 394.19% upside). 6 analyst firms have reported ratings in the last year.
The stock price for Ocuphire Pharma (NASDAQ: OCUP) is $3.44 last updated September 29, 2023 at 9:55 PM UTC.
There is no dividend information for Ocuphire Pharma.
Ocuphire Pharma’s Q3 earnings are confirmed for Friday, November 3, 2023.
There is no upcoming split for Ocuphire Pharma.
Ocuphire Pharma is in the Health Care sector and Pharmaceuticals industry. They are listed on the NASDAQ.
Ocuphire Pharma Stock (NASDAQ: OCUP) stock price, news, charts, stock research, profile.
Open3.520 | Close3.350 |
Vol / Avg.768.088K / 210.509K | Mkt Cap73.040M |
Day Range3.090 - 3.558 | 52 Wk Range1.960 - 6.600 |
Q3 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED) | ||||||
REV |
Q2 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -0.230 | -0.240 | -0.0100 | ||||
REV | 2.420M | 3.674M | 1.254M |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|---|---|---|---|---|---|---|
2023-08-14 | Cantor Fitzgerald | Kristen Kluska | Reiterates | OverweightOverweight | Maintains | - | 17.00 |
2023-08-14 | HC Wainwright & Co. | Matthew Caufield | Reiterates | BuyBuy | Maintains | - | 20.00 |
2023-05-16 | HC Wainwright & Co. | Matthew Caufield | Reiterates | BuyBuy | Maintains | - | 20.00 |
2023-03-31 | HC Wainwright & Co. | Matthew Caufield | Reiterates | Buy | Maintains | - | 20.00 |
Ticker | Company | Chg % | Mkt Cap |
---|---|---|---|
OCUP | Ocuphire Pharma | -1.15% | 73M |
SCYX | SCYNEXIS | 2.17% | 87.4M |
RANI | Rani Therapeutics Hldgs | -17.74% | 55.7M |
AQST | Aquestive Therapeutics | -0.67% | 99.4M |
ESPR | Esperion Therapeutics | 3.34% | 105.9M |
You can purchase shares of Ocuphire Pharma (NASDAQ: OCUP) through any online brokerage.
Other companies in Ocuphire Pharma’s space includes: SCYNEXIS (NASDAQ:SCYX), Rani Therapeutics Hldgs (NASDAQ:RANI), Aquestive Therapeutics (NASDAQ:AQST), Esperion Therapeutics (NASDAQ:ESPR) and Incannex Healthcare (NASDAQ:IXHL).
The latest price target for Ocuphire Pharma (NASDAQ: OCUP) was reported by Cantor Fitzgerald on Monday, August 14, 2023. The analyst firm set a price target for 17.00 expecting OCUP to rise to within 12 months (a possible 394.19% upside). 6 analyst firms have reported ratings in the last year.
The stock price for Ocuphire Pharma (NASDAQ: OCUP) is $3.44 last updated September 29, 2023 at 9:55 PM UTC.
There is no dividend information for Ocuphire Pharma.
Ocuphire Pharma’s Q3 earnings are confirmed for Friday, November 3, 2023.
There is no upcoming split for Ocuphire Pharma.
Ocuphire Pharma is in the Health Care sector and Pharmaceuticals industry. They are listed on the NASDAQ.
Ocuphire Pharma Stock (NASDAQ: OCUP) stock price, news, charts, stock research, profile.
Open3.520 | Close3.350 |
Vol / Avg.768.088K / 210.509K | Mkt Cap73.040M |
Day Range3.090 - 3.558 | 52 Wk Range1.960 - 6.600 |
Q3 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED) | ||||||
REV |
Q2 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -0.230 | -0.240 | -0.0100 | ||||
REV | 2.420M | 3.674M | 1.254M |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|---|---|---|---|---|---|---|
2023-08-14 | Cantor Fitzgerald | Kristen Kluska | Reiterates | OverweightOverweight | Maintains | - | 17.00 |
2023-08-14 | HC Wainwright & Co. | Matthew Caufield | Reiterates | BuyBuy | Maintains | - | 20.00 |
2023-05-16 | HC Wainwright & Co. | Matthew Caufield | Reiterates | BuyBuy | Maintains | - | 20.00 |
2023-03-31 | HC Wainwright & Co. | Matthew Caufield | Reiterates | Buy | Maintains | - | 20.00 |
Ticker | Company | Chg % | Mkt Cap |
---|---|---|---|
OCUP | Ocuphire Pharma | -1.15% | 73M |
SCYX | SCYNEXIS | 2.17% | 87.4M |
RANI | Rani Therapeutics Hldgs | -17.74% | 55.7M |
AQST | Aquestive Therapeutics | -0.67% | 99.4M |
ESPR | Esperion Therapeutics | 3.34% | 105.9M |
You can purchase shares of Ocuphire Pharma (NASDAQ: OCUP) through any online brokerage.
Other companies in Ocuphire Pharma’s space includes: SCYNEXIS (NASDAQ:SCYX), Rani Therapeutics Hldgs (NASDAQ:RANI), Aquestive Therapeutics (NASDAQ:AQST), Esperion Therapeutics (NASDAQ:ESPR) and Incannex Healthcare (NASDAQ:IXHL).
The latest price target for Ocuphire Pharma (NASDAQ: OCUP) was reported by Cantor Fitzgerald on Monday, August 14, 2023. The analyst firm set a price target for 17.00 expecting OCUP to rise to within 12 months (a possible 394.19% upside). 6 analyst firms have reported ratings in the last year.
The stock price for Ocuphire Pharma (NASDAQ: OCUP) is $3.44 last updated September 29, 2023 at 9:55 PM UTC.
There is no dividend information for Ocuphire Pharma.
Ocuphire Pharma’s Q3 earnings are confirmed for Friday, November 3, 2023.
There is no upcoming split for Ocuphire Pharma.
Ocuphire Pharma is in the Health Care sector and Pharmaceuticals industry. They are listed on the NASDAQ.
Ocuphire Pharma Stock (NASDAQ: OCUP) stock price, news, charts, stock research, profile.
Open3.520 | Close3.350 |
Vol / Avg.768.088K / 210.509K | Mkt Cap73.040M |
Day Range3.090 - 3.558 | 52 Wk Range1.960 - 6.600 |
Q3 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED) | ||||||
REV |
Q2 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -0.230 | -0.240 | -0.0100 | ||||
REV | 2.420M | 3.674M | 1.254M |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|---|---|---|---|---|---|---|
2023-08-14 | Cantor Fitzgerald | Kristen Kluska | Reiterates | OverweightOverweight | Maintains | - | 17.00 |
2023-08-14 | HC Wainwright & Co. | Matthew Caufield | Reiterates | BuyBuy | Maintains | - | 20.00 |
2023-05-16 | HC Wainwright & Co. | Matthew Caufield | Reiterates | BuyBuy | Maintains | - | 20.00 |
2023-03-31 | HC Wainwright & Co. | Matthew Caufield | Reiterates | Buy | Maintains | - | 20.00 |
Ticker | Company | Chg % | Mkt Cap |
---|---|---|---|
OCUP | Ocuphire Pharma | -1.15% | 73M |
SCYX | SCYNEXIS | 2.17% | 87.4M |
RANI | Rani Therapeutics Hldgs | -17.74% | 55.7M |
AQST | Aquestive Therapeutics | -0.67% | 99.4M |
ESPR | Esperion Therapeutics | 3.34% | 105.9M |
You can purchase shares of Ocuphire Pharma (NASDAQ: OCUP) through any online brokerage.
Other companies in Ocuphire Pharma’s space includes: SCYNEXIS (NASDAQ:SCYX), Rani Therapeutics Hldgs (NASDAQ:RANI), Aquestive Therapeutics (NASDAQ:AQST), Esperion Therapeutics (NASDAQ:ESPR) and Incannex Healthcare (NASDAQ:IXHL).
The latest price target for Ocuphire Pharma (NASDAQ: OCUP) was reported by Cantor Fitzgerald on Monday, August 14, 2023. The analyst firm set a price target for 17.00 expecting OCUP to rise to within 12 months (a possible 394.19% upside). 6 analyst firms have reported ratings in the last year.
The stock price for Ocuphire Pharma (NASDAQ: OCUP) is $3.44 last updated September 29, 2023 at 9:55 PM UTC.
There is no dividend information for Ocuphire Pharma.
Ocuphire Pharma’s Q3 earnings are confirmed for Friday, November 3, 2023.
There is no upcoming split for Ocuphire Pharma.
Ocuphire Pharma is in the Health Care sector and Pharmaceuticals industry. They are listed on the NASDAQ.